Status:
COMPLETED
Study of XL647 Administered Orally Daily to Patients With Solid Tumors
Lead Sponsor:
Kadmon Corporation, LLC
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the safety and tolerability of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR, VEGFR2, ErbB2, and EphB4) XL647 when given orally daily to ...
Eligibility Criteria
Inclusion
- Subject has histologically confirmed malignancy that is metastatic or unresectable
- Subject has disease that is assessable by tumor marker, physical, or radiologic means
- Subject is at least 18 years old
- Subject has an ECOG performance status ≤ 2 (Karnofsky ≥ 60%)
- Subject has a life expectancy ≥ 3 months
- Subject has normal organ and marrow function
- Subject gives written informed consent
- Subject must use an accepted method of contraception during the study
- Female subjects of childbearing potential must have a negative pregnancy test
Exclusion
- Subject has received anticancer treatment within 30 days of first dose of XL647
- Subject has received another investigational agent within 30 days of first dose of XL647
- Subject has known brain metastases
- Subject has corrected QT interval (QTc) of \> 0.45 seconds
- Subject is currently receiving anticoagulation therapy with warfarin
- Subject has uncontrolled intercurrent illness
- Subject is pregnant or breastfeeding
- Subject has known HIV
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT00336765
Start Date
July 1 2006
End Date
September 1 2010
Last Update
May 13 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University Medical Center
Stanford, California, United States, 94305
2
Mayo Clinic
Rochester, Minnesota, United States, 55905